Since therapeutic targeting of HER2 or VEGF alone does not provide adequate tumor control in many of the treated patients [52, 53], evaluation of newer targeted approaches with or without other anti-HER2 therapies may be relevant to inhibit pathologic angiogenesis in HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.